국가: 아일랜드
언어: 영어
출처: HPRA (Health Products Regulatory Authority)
LEVOFLOXACIN
PCO Manufacturing
500 Milligram
Film Coated Tablet
2009-08-28
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tavanic 500mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet of Tavanic contains 500mg of levofloxacin as active substance corresponding to 512.46mg of levofloxacin hemihydrate For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet _Product imported from the UK:_ Score line, pale, yellowish-white to reddish-white film-coated tablets 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In adults with infections of mild or moderate severity, Tavanic tablets are indicated for the treatment of the following infections when due to levofloxacin-susceptible microorganisms: Acute bacterial sinusitis (adequately diagnosed according to national and/or local guidelines on the treatment of respiratory tract infections) Acute bacterial exacerbations of chronic bronchitis (adequately diagnosed according to national and/or local guidelines on the treatment of respiratory tract infections) Community-acquired pneumonia Complicated urinary tract infections including pyelonephritis Chronic bacterial prostatitis. Skin and soft tissue infections. Before prescribing Tavanic, consideration should be given to national and/or local guidance on the appropriate use of fluoroquinolones. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Tavanic tablets are administered once or twice daily. The dosage depends on the type and severity of the infection and the sensitivity of the presumed causative pathogen. _DURATION OF TREATMENT_ The duration of treatment varies according to the course of the disease (see table below). As with antibiotic therapy in general, administration of Tavanic tablets should be continued for a minimum of 48 to 72 hours after the patient has become afebrile or evidence of bacteri 전체 문서 읽기